-- Second Phase 3 study achieves primary and key secondary endpoints; safely demonstrating statistically significant reductions in postsurgical pain and opioid consumption through 96 hours --
-- Company on track to submit supplemental New Drug Application in first quarter of 2023 --
https://finance.yahoo.com/news/pacira-biosciences-announces-positive-topline-120000563.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.